Aiping P. Zhou
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 105 publications
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.
Journal: Nature medicine
Published: April 17, 2026
Case Report: Patient-derived organoids guiding dabrafenib-trametinib therapy in BRAFV600E-mutant metastatic gastric cancer.
Journal: Frontiers in oncology
Published: February 19, 2026
PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with hepatocellular carcinoma receiving PD-(L)1 blockade and targeted therapy.
Journal: Journal for immunotherapy of cancer
Published: December 12, 2025
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.
Journal: The New England journal of medicine
Published: October 22, 2025
Minimum 18-week chemotherapy improves survival in locally advanced rectal cancer after neoadjuvant radiotherapy: a post hoc analysis of the STELLAR trial.
Journal: BMC medicine
Published: October 15, 2025
Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study.
Journal: ESMO open
Published: October 08, 2025
Serum BDNF helps identify favorable subgroups in HCC patients treated with PD-L1 inhibitors and anti-angiogenic TKIs.
Journal: Therapeutic advances in medical oncology
Published: August 22, 2025
Pyrotinib Plus Trastuzumab as an Effective Later-Line Therapeutic Strategy for HER2-Positive Metastatic Colorectal Cancer: Results from a Phase II Study.
Journal: Drug design, development and therapy
Published: August 05, 2025
Tumor Immune Microenvironment and Current Status of Immune Checkpoint Inhibitor Therapy in Colorectal Cancer Liver Metastasis.
Journal: Current oncology (Toronto, Ont.)
Published: July 09, 2025
Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer.
Journal: Human vaccines & immunotherapeutics
Published: February 24, 2025
Comparison of Al 18 F-NOTA-FAPI-74 and 18 F-FDG PET/CT in the Evaluation and Staging of Hepatobiliary Malignancies : A Single-center Prospective Study.
Journal: Clinical nuclear medicine
Published: January 17, 2025
CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial.
Journal: Nature medicine
Published: December 10, 2024
Last Updated: 09/26/2026